Douglas B. Sawyer – författare

This issue of the Heart Failure Clinics of North America, guest edited by Drs. Daniel Lenihan and Douglas Sawyer, will cover several aspects of Cardio-oncology Related to Heart Failure. Subjects discussed in the volume include, but are not limited to: Proteasome Inhibitors as a potential cause of Heart Failure; EGFR target based therapy; Amyloidosis; How to manage Heart Failure in a patient with cancer; Advanced HF/Txp; Epidemiology and common risk factors; Pediatric Considerations; Alternative biomarkers for combined biology; How to develop a Cardio-Oncology Clinic; and How to structure a Cardio-Oncology fellowship program, among others.

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.� Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.� This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics:• Cardiac complications in patients receiving cancer therapy• The treatment of cancer in patients with cardiovascular disease• The treatment of cardiovascular disease in patients with cancerWhen relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.